Table 1 Baseline characteristics of the patients

From: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

Patient's characteristics

# of patients (%)

Total number

55 (100%)

Male/female

21/34 (38.2%/61.8%)

Age (years)

 Median

63

 Range

27–79

Performance status

 ECOG 0

26 (47.3%)

 ECOG 1

18 (32.7%)

 ECOG 2

11 (20.0%)

Primary tumour site

 Colon

38 (69.1%)

 Rectum

17 (30.9%)

No of metastatic sites

 1

16 (29.1%)

 2

26 (47.3%)

 3+

13 (23.6%)

Sites of metastases

 Liver

33 (60.0%)

 Lung

23 (41.8%)

 Nodes

19 (34.5%)

 Local

12 (21.8%)

 Other

24 (43.6%)

Prior adjuvant therapy

 None

14 (25.4%)

 FU/LV

32 (58.2%)

First-line regimen

 XELOX

38 (69.1%)

 FOLFOX

17 (30.9%)

Second-line regimen

 FOLFIRI

55 (100%)

EGFR expression

 Score 1

16 (29.1%)

 Score 2

20 (36.4%)

 Score 3

19 (34.5%)

Back to article page